Japan Earthquake Disrupts Auto and Chip Supply Chains 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
NEW ORLEANS, April 13, 2018 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (NasdaqGS:SLDB), if they purchased the Company’s shares between January 25, 2018, and March 14, 2018 (the “Class Period”) or in its January 25, 2018 initial public offering (“IPO”). This action is pending in the United States District Court for the District of Massachusetts.
Get Help
Solid Biosciences investors should visit us at https://www.claimsfiler.com/cases/view-solid-biosciences-inc-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Solid Biosciences and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On January 30, 2018, a report co-authored by a former scientific advisor of the Company revealed risks of high systemic dosing using the Company’s delivery system, AAV or adeno-associated virus, for its lead drug candidate SGT-001. Then, on March 14, 2018, the Company disclosed a clinical hold placed on the SGT-001 trial by the FDA relating to adverse events.
On this news, the price of Solid Biosciences’ shares plummeted over 60% to $9.32/share on March 15, 2018.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
